Jones Trading analyst Catherine Novack reiterated a Buy rating and $51.00 price target on Capricor Therapeutics (NASDAQ: CAPR).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

H.C. Wainwright on Capricor Therapeutics (CAPR): 'Cage Match Expected at Wednesday's AdCom as Drama with FDA Continues'July 27, 2026 12:31 PM B.Riley Downgrades Capricor Therapeutics (CAPR) to NeutralJuly 27, 2026 11:02 AM Capricor disputes FDA briefing materials ahead of deramiocel reviewJuly 27, 2026 11:00 AM Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for DeramiocelJuly 27, 2026 11:00 AM Increasing unusual put option volume: CAPR BETA UCO CRH BKR METC OTLK CIA TCOM EQNRJuly 27, 2026 10:48 AM Oppenheimer Reiterates Capricor Therapeutics (CAPR) at Outperform, 'like the risk-reward'July 27, 2026 10:12 AM Capricor Therapeutics (CAPR) Falls 26% Following FDA Briefing Docs PostJuly 27, 2026 7:55 AM